Introduction {#S1}
============

Diabetic nephropathy (DN) is the primary cause of chronic kidney disease. Despite therapeutic advances, DN remains the principal cause of mortality in diabetic patients ([@B27]).

Renin--angiotensin system (RAS) has been classically involved in the progression of diabetic cardiovascular disease. A chronically activated endocrine or paracrine RAS is considered as a principal contributor to the pathophysiology of end-organ damage in diabetes mellitus (DM), including the DN ([@B77]). As a result, therapeutic drugs for DN are targeting mostly the renin--angiotensin--aldosterone system ([@B85]).

Although debate remains, the therapeutic drugs for DN currently consist mainly of angiotensin II (Ang II) receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) used for their antihypertensive and antiproteinuric measures ([@B11]). Direct renin inhibitors (DRIs) acting on rate-limiting enzyme of the RAS offered probability of a greater inhibition of the system so as to have better therapeutic outcomes in patients with DN ([@B58]). The rationale for developing renin inhibitors was as follows: renin is the first and rate-limiting step in RAS cascade (low renin concentration in the pM range), renin has high specificity for angiotensinogen (little side effects anticipated), ACEIs and ARBs result in incomplete RAS suppression \[reactive rise in plasma renin activity (PRA), "escape" mechanism, and other products of RAS (e.g., Ang1--7, AIII, and AIV)\] ([@B83]; [@B55]; [@B73]). However, larger trials of the DRI aliskiren in combination with an ACE inhibitor or ARB in patients with DN did not reduce cardiovascular or renal outcomes ([@B57]).

Plasma renin activity played a central role as a pharmacological biomarker for drug development, safety, and dosing in the research and development (R&D) of DRIs such as remikiren, enalkiren, zankiren, and aliskiren. Generally, DRIs induced rapid reductions of 65--95% PRA ([@B50]). PRA has been used in the estimation of the extracellular volume, because this correlates inversely with PRA ([@B41]). Hence, [@B14] categorized hypertensive patients by their volume status using PRA levels. Augmented PRA levels represent a risk factor of cardiovascular disease ([@B3]; [@B56]). Whereas several pathologies are associated with an augmented PRA, DM and associated DN apparently are not.

The therapeutic effects of RAS inhibitors may be important depending on the pathological activation of endocrine and/or tissue RAS ([@B37]; [@B21]). For instance, disease conditions with low baseline PRA levels reduced the treatment efficacy of DRIs ([@B74]). Few reviews on DRI for DN as therapeutic target discussed PRA as an outcome measure ([@B1]; [@B68]; [@B40]). These reviews document that PRA is reduced in DM with or without DN.

Early studies described hyporeninemia or low-renin state as a characteristic state of circulatory RAS in DM patients with or without DN ([@B72]). Our and other studies ([@B21]; [@B72]) evidencing a diabetes-induced low-renin status may indicate that a DRI is not always effective in treating DN. Therefore, the purpose of this study was to examine and synthesize the existing literature on DRI effects on PRA in DN. Literature search included studies that investigated DRIs such as remikiren, enalkiren, zankiren, or aliskiren in DN.

Methods {#S2}
=======

Literature Search Strategy {#S2.SS1}
--------------------------

We conducted a systematic review of investigative studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) consensus guidelines ([@B53]). A literature search of the MEDLINE database via PubMed was performed using a structured approach to identify relevant studies. A manual search was also conducted through searching the reference lists of relevant articles to expand the included studies. Eligibility assessment of identified articles was performed independently by two reviewers for preclinical studies and two reviewers for clinical studies, and inconsistencies were settled by one of the senior reviewers.

Inclusion Criteria {#S2.SS2}
------------------

To identify relevant articles on original research, we associated terms referring to the use of PRA and/or renin inhibitors in DN. All experimental studies on humans and animals were eligible. Document types included were those produced as original and review papers written in English and published until 2018. The following Medical Subject Headings (MeSH) were used in the search: DN OR "diabetic kidney disease" AND "renin inhibitor" OR "aliskiren" OR "remikiren" OR "enalkiren" OR "zankiren." We used filters to select the type of study, and we gathered data from clinical trials and from case--control and cohort studies and reviews, designed to assess the effects of DRIs on PRA in DN.

Exclusion Criteria {#S2.SS3}
------------------

Articles were excluded if they were clinical case reports, clinical case series, letters, editorials, opinions, points of views, or anecdotes. Also, articles that were written in languages other than English were discarded.

Data Extraction and Quality Assessment {#S2.SS4}
--------------------------------------

Four investigators evaluated independently titles and abstracts and selected the articles for further full-text evaluation. Disagreements were resolved by consensus or by consultation with one of the senior investigators. When data were not found in the published article, authors were contacted to provide the missing information. The following data were collected: title, author and study group, publication year, DN, DRI, and PRA.

Results {#S3}
=======

Search Results and Study Selection {#S3.SS1}
----------------------------------

[Figure 1](#F1){ref-type="fig"} details the search and selection process of articles that determined (or discussed in case of reviews) PRA when investigating DRI effects in DN. Of 920 potentially relevant papers initially identified through the PubMed search, after de-duplication, we reviewed 918 titles and abstracts; from these, we included 878 in a full-text review. A further 873 articles were excluded after full review, and five were included in the present study: one preclinical study and four clinical studies.

![PRISMA Flow Diagram.](fphys-11-00190-g001){#F1}

Clinical Studies With Direct Renin Inhibitor in Diabetic Nephropathy That Determined Plasma Renin Activity {#S3.SS2}
----------------------------------------------------------------------------------------------------------

Three clinical studies have been identified to have reported effects of DRI (aliskiren) on PRA in DN ([Table 1](#T1){ref-type="table"}). Two studies reported a significant decrease of albuminuria associated with PRA reduction ([@B65]; [@B2]). The *post hoc* analysis of ALTITUDE study ([@B57]) in a subset of 133 patients reported a non-significant reduction of urinary albumin creatinine of 22 and 9% in the aliskiren and placebo groups, respectively ([@B61]).

###### 

Clinical Studies with DRI in diabetic nephropathy that determined plasma renin activity.

  **Study**   **Study type**                                      **DRI monotherapy/add-in therapy**                                                          **Study participants**                                                                                                  **Renal outcomes**                                                                                           **DRI effect on PRA**
  ----------- --------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------
  [@B65]      Double-blind, randomized, crossover trial           Aliskiren, irbesartan, and aliskiren/irbesartan, 2-month treatment                          26 patients with T2DM, HTN, and albuminuria (\>100 mg/day)                                                              Significant reduction in urinary albumin, glomerular filtration rate, and 24-h blood pressure from placebo   72%↓ as monotherapy compared with placebo
  [@B61]      AVOID *post hoc* analysis                           Add-in: aliskiren or placebo in addition to losartan, 6-month treatment                     Patients with HTN and T2DM with nephropathy: a prespecified subset of 133 (22%) patients from a total of 599 patients   Not significant reduction in urinary albumin--creatinine ratio                                               71%↓ compared with placebo (90%↓ compared with baseline; placebo: 19%↓)
  [@B2]       Open-label, randomized, parallel-controlled study   Add-in: aliskiren or placebo in addition to telmisartan and amlodipine, 6-month treatment   64 patients with T2DM, DN, and HTN                                                                                      Significant reduction in urinary albumin--creatinine ratio                                                   70--77%↓ compared with baseline; 89%↓ compared with calcium channel blocker (CCB) group

T2DM, type 2 diabetes mellitus; DN, diabetic nephropathy; HTN, hypertension; PRA, plasma renin activity; DRI, direct renin inhibitor.

One double-blind, randomized study that investigated the effect of aliskiren as monotherapy in patients with DM and hypertension (HTN) reported a decrease of 72% in PRA ([@B65]). Two other studies that investigated aliskiren or placebo in addition to an ARB \[one a *post hoc* analysis ([@B61]) and the other an open-label, randomized study ([@B2])\] reported a PRA decrease of 71--77%. The data from the studies were heterogeneous and not sufficient to carry out a quantitative analysis. There were not enough data in two studies ([@B2]; [@B61]), the reported PRA data had a skewed distribution in one study ([@B65]), and there was no blindness in one study ([@B2]). In addition, in one study, PRA was determined only in a subset of patients from the total investigated in the aliskiren group: 22% (133 of 599) patients in the ([@B61]) study.

Of 10,393 patients with DN enrolled in five studies \[599 in [@B58]; 26 in [@B65]; 8,561 in the ALTITUDE study ([@B57]); 64 in [@B2]; 1,143 in the VIvID study ([@B8])\], 370 (3.6%) patients had PRA measured ([@B65], [@B61]; [@B2]).

Preclinical Studies With Direct Renin Inhibitor in Diabetic Nephropathy That Determined Plasma Renin Activity {#S3.SS3}
-------------------------------------------------------------------------------------------------------------

One preclinical proof-of-concept study testing the effects of aliskiren in DN determined PRA ([Table 2](#T2){ref-type="table"}). This study used as model for DM the streptozotocin (STZ)-induced DM in C57BL/6J mice fed on a high-fat diet, determined PRA, and found higher levels in DN when compared with the control non-DN ([@B44]). In [Table 2](#T2){ref-type="table"} are included articles that reported renal renin outcome measures, including plasma renin concentration and renin mRNA expression.

###### 

Preclinical studies with DRI in diabetic nephropathy that determined plasma renin or renal RAS.

  **Study**   **Experimental model**                               **DRI**                          **Outcome**                                                                                     **Renal/plasma renin in DN control vs. healthy control**                                  **Effects of DRI on renal/plasma renin**
  ----------- ---------------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------
  [@B25]      db/db mice, with obesity and T2DM                    Aliskiren, 6 weeks' treatment    Protects against cardiovascular complications and pancreatic injury                             Renal renin mRNA not different than that of control db/m mice                             Increased renal renin mRNA expression
  [@B26]      db/db mice with obesity and T2DM                     Aliskiren, 6 weeks' treatment    Protects against DN                                                                             Renal renin mRNA higher than that in control db/m mice                                    Increased renal renin mRNA expression
  [@B42]      db/db mice with obesity and T2DM                     Aliskiren, 3 months' treatment   Decreased albuminuria, glomerulosclerosis, interstitial fibrosis, improved insulin resistance   Lower plasma renin concentration (PRC) in db/db mice than in db/m mice (control non-DM)   Increased PRC
  [@B80]      STZ-DBA/2J mice fed on a high-fat diet               Aliskiren, 6 weeks' treatment    Protects against DN                                                                             Renal renin mRNA in DN higher than that in control non-DN                                 Increased renal renin mRNA expression
  [@B87]      db/db mice, with obesity and T2DM + uninephrectomy   Aliskiren, 4 weeks' treatment    Protects against DN                                                                             PRC normal, renal renin mRNA higher than that in control non-DN                           Increased PRC and renal renin mRNA expression
  [@B44]      STZ-C57BL/6J mice fed on a high-fat diet             Aliskiren, 4 weeks' treatment    Protects against DN                                                                             PRA and *in vivo* imaging of renal renin activity higher than that in control non-DN      Decreased PRA and *in vivo* imaging of renal renin activity

T2DM, type 2 diabetes mellitus; DRI, direct renin inhibitor; RAS, renin--angiotensin system; DN, diabetic nephropathy.

Discussion {#S4}
==========

The present study shows that a low number of preclinical and clinical studies with DRIs as monotherapy or add-in therapy in DN assessed PRA. Only two randomized controlled studies reported renoprotective effects in DN associated with a significant reduction in PRA.

Of eight publications identified to report DRI effects on urinary albumin in DN ([@B58], [@B57]; [@B65], [@B63], [@B64], [@B61],[@B62]; [@B2]), only three clinical studies presented data on PRA. All three involved patients with both DM and HTN. As aliskiren does not lower blood pressure in hypertensive patients with low PRA ([@B70]), [@B40] suggested that "it may be useful to dichotomize RAAS-related pathologic syndromes into ones associated with high renin (some HTN, any HTN after diuretic treatment), where aliskiren appears to be quite effective, and low-renin" (like diabetes), where aliskiren is of uncertain value. Indeed, in the AVOID study ([@B58]), a prespecified subset of 133 (22%) patients from a total of 599 patients was identified with a significant decrease in PRA by aliskiren ([@B61]). The study of [@B76] that reported a significant reduction in 24-h ambulatory blood pressure presented PRA data on 32% of the total patients recruited in the DRI study group. As such, important information that could lead to patient stratification could be learned from disclosing the PRA data from the ALTITUDE study ([@B57]).

Dual therapy of the DRI aliskiren with ACEI or ARBs was commonly investigated in patients with HTN, heart failure, and diabetes with or without proteinuria. It is conceptualized that the antihypertensive efficacy of aliskiren is increased when adding ACEIs, ARBs, or diuretics, which produce a reactive increase in PRA. Indeed, aliskiren in combination with ACEIs or ARBs showed significant blood pressure and proteinuria reductions than monotherapy alone in phase II trials with hypertensive patients with or without DM ([@B65]), reviewed by [@B71]. Clinical trials that studied the combination of aliskiren and ACEI or ARBs and involved patients with DM include Pool 2007, ALOFT 2008, ALLAY 2009, AVANTE GARDE 2010, VANTAGE 2010, and ASPIRE 2011. These studies were systematically reviewed by [@B38]. They were not designed to investigate outcomes in DM patients. A meta-analysis of 13,395 patients with diabetes showed no benefit from the addition of aliskiren to standard medical therapy ([@B86]).

Finding a preclinical experimental model for DM and DN was challenged by the high selectivity of aliskiren for human renin compared with renin from other species (IC50 values \[50% inhibitory concentrations\]: human 0.6, marmoset 2, rat 80, dog 7) ([@B84]). The first studies of DRI on an experimental DM model used the STZ-induced DM in high-renin hypertensive (mRen-2)27 rats ([@B43]; [@B30]). However, this DM model cannot consider the phenotype alterations as primarily induced by DM because these rats genetically activated renin production. Four studies reported DRI effects on DN of db/db mice ([Table 2](#T2){ref-type="table"}). Another study on db/db mice showed no significant differences in their PRA compared to control db/m mice ([@B35]).

Experimental models investigated for proof-of-concept efficacy of aliskiren in DN were db/db mice for type 2 DM (T2DM) and STZ mice (DBA/2J and C57BL/6J strains) for type 1 DM (T1DM). The db/db mice are characterized by T2DM, elevated systolic blood pressure, obesity, and hyperlipidemia. They develop T2DM with high plasma levels of insulin and glucose at weeks 9--10 of age ([@B33]). The main outcomes studied for DN, including increased albumin excretion and glomerular pathology, are very similar between mouse lines with T1DM or T2DM and humans with DM ([@B6]).

Locally activated synthesis and activity of renin have been identified in kidney and other organs in different pathologies ([@B7]). Such organs where a local tissue RAS has been postulated include the heart, blood vessels, kidney, brain, adipose tissue, adrenal gland, pancreas, liver, reproductive system, lymphatic tissue, placenta, and eyes ([@B54]). Diseases where chronically activated local tissue RAS has been identified include HTN, atherosclerosis, heart failure, cardiac hypertrophy and fibrosis, chronic kidney disease, and glaucoma ([@B4]; [@B54]). An increase in local production of active angiotensins could be through the classical renin--ACE pathway or through alternative pathways ([@B32]). Translational proof-of-concept studies shall distinguish the enzymes involved in these RAS pathways in order to identify therapeutic targets. For instance, we have demonstrated in a proof-of-concept study that renin might be a therapeutic target in glaucoma ([@B79]). This does not seem to be the case in DN where both preclinical and clinical proof-of-concept studies indicate that DN is associated with a low-renin state. In [Table 3B](#T3B){ref-type="table"}, we summarized the clinical studies that described hyporeninemia in DM, with the first report dated year 1973. These studies indicate that hyporeninemic hypoaldosteronism is underdiagnosed in DM ([@B72]). Several mechanisms have been suggested as responsible for the reduction in renin release in patients with DM, including juxtaglomerular injury, autonomic dysfunction, and primary increase in renal salt retention with volume expansion ([@B66]; [@B72]). The first experimental studies of RAS in DM used alloxan-DM or STZ-DM rat models ([Table 3A](#T3A){ref-type="table"}). Preclinical evidence for an activated renal RAS in DM is suggested by our and others studies on increased synthesis and urinary secretion of renal angiotensinogen ([@B88]; [@B69]; [@B21]; [@B51]) ([Figure 2](#F2){ref-type="fig"} shows urinary angiotensinogen as a potential biomarker). STZ-induced DM in rats caused a 69% increase of Ang II in the renal interstitial fluid, which was decreased 27% by aliskiren (6 weeks' treatment) ([@B52]). As aliskiren did not normalize the DM-increased renal interstitial fluid Ang II, alternative Ang II-forming pathways might have been activated. One candidate enzyme that may take over the renin activity in kidney to activate the local Ang II production is cathepsin L. Cathepsin L was identified as a potential sex-specific biomarker for renal damage by the Actelion group ([@B10]). Cathepsin L appears to be importantly involved in the development of albuminuria and renal damage in early experimental DN ([@B36]) ([Figure 2](#F2){ref-type="fig"}). Angiotensinogen may be degraded by cathepsins including cathepsin L, which may degrade angiotensinogen ([@B81]). As cathepsin L can be involved in the pathogenesis of DN through several mechanisms, targeting with suitable antagonists may hold promises for therapeutic interventions ([@B49]). PRA is not a good indicator of local RAS activity as measure circulating production of angiotensin I, where ACE, alternative Ang II-forming enzymes, and Ang II might be increased in the local tissue. Although PRA is a pharmacological efficacy biomarker for aliskiren and has been considered as an outcome measure in DM, the effects of renin inhibitors on local tissue RAS are not easily demonstrable in clinical studies because there are no available biomarkers for local RAS activation. Studies on urinary peptidome might lead to the characterization of biomarkers for local renal RAS activation, such as cathepsin L or D ([@B47]).

###### 

Preclinical studies that determined PRA in experimental DM.

  **Study**   **Experimental model**                              **DM effect on PRA**
  ----------- --------------------------------------------------- -------------------------------------------------------------------------------------------
  [@B16]      Alloxan-DM rat, acute DM (alloxan is nephrotoxic)   Low PRA
  [@B19]      Alloxan-DM rat, 3 months                            PRA decreased progressively
  [@B9]       STZ-DM rat, 1 month                                 PRC values in untreated DM rats were lower than those of insulin-treated rats or controls
  [@B67]      Alloxan-DM rat, 7 weeks                             Low PRA
  [@B45]      STZ-DM rat, 1.5 months                              Hyporeninemic hypoaldosteronism
  [@B46]      STZ-DM rat, 2 months                                Hyporeninemic hypoaldosteronism
  [@B24]      Alloxan-DM rat, 1 month                             Low PRA, glucose overload did not significantly affect these values
  [@B21]      STZ-DM rat, 3 months                                Low PRA, PRC, and renal renin mRNA

PRA, plasma renin activity; DN, diabetic nephropathy; DM, diabetes mellitus; STZ, streptozotocin.

###### 

Clinical studies on low PRA in DN.

  **Study**   **Study participants**                                **PRA in DM**
  ----------- ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  [@B15]      One patient with DM                                   Hyporeninemic hypoaldosteronism
  [@B23]      Two patients with DM                                  Hypoaldosteronism due to low PRA
  [@B39]      31 Patients with T1DM                                 Intrarenal RAS activated without PRA
  [@B12]      80 Patients with T1DM                                 Low PRA and high plasma ANP
  [@B28]      One patient with DM                                   Hyporeninemic, hypoaldosteronism, and autonomic neuropathy
  [@B13]      One patient with DM                                   Hyporeninemic hypoaldosteronism
  [@B34]      118 Patients with DM                                  Hyporeninemic selective hypoaldosteronism may be associated with DM nephropathy or DM neuropathy
  [@B59]      100 Teenage patients with T1DM                        Decline of PRA over 5 years
  [@B78]      13 Patients with DM and chronic renal failure         Hyporeninemic hypoaldosteronism associated with type IV renal tubular acidosis
  [@B5]       12 Patients with DM                                   Low PRA and active renin (AR)
  [@B31]      16 Normotensive diabetics with long-term disease      Hyporeninemia
  [@B29]      Four patients with DM                                 Diabetic hyporeninemic hypoaldosteronism
  [@B75]      Five patients with DM with mild renal insufficiency   Hyporeninemic hypoaldosteronism associated with DM and neuropathy may be due to decreased sympathetic nervous system activity
  [@B48]      Three patients with DM                                Hyporeninemic hypoaldosteronism
  [@B18]      44 Patients with DM                                   Hyporeninemic hypoaldosteronism is frequent in diabetics with nephropathy
  [@B17]      48 Patients with DM                                   \(1\) PRA is normal in normotensive diabetics (2) Patients with diabetes, hypertension, and nephropathy have "low renin hypertension"
  [@B20]      Eight patients with DM                                Low PRA
  [@B22]      60 Patients with DM                                   Low PRA
  [@B60]      12 Patients with DM                                   Hyporeninemia and hypoaldosteronism
  [@B82]      Four patients with DM                                 Low PRA

PRA, plasma renin activity; DN, diabetic nephropathy; DM, diabetes mellitus; RAS, renin--angiotensin system; ANP, atrial natriuretic peptide; T1DM, type 1 diabetes mellitus.

![Renal renin-angiotensin system in diabetes mellitus. AOGEN, angiotensinogen; ACE, angiotensin-converting enzyme; Ang, angiotensin; AT1, angiotensin type 1 receptor.](fphys-11-00190-g002){#F2}

Conclusion {#S5}
==========

Very few studies addressed the PRA as the outcome measure of DRI treatment effect in DN. Therefore, for a more successful translational research, specific patient population where DRI treatment is effective in DN should be identified. Additional well-designed randomized controlled trials (RCTs) using PRA as a marker for patient stratification and randomization may be warranted.
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